Virtu KCG Holdings’s BioMarin Pharmaceuticals BMRN Stock Holding History

Virtu KCG Holdings’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$2.24M	Buy	24,643 +9,149	+59%	+$832K	0.06%	211
2017 Q1	$1.36M	Buy	15,494 +1,329	+9%	+$118K	0.04%	493
2016 Q4	$1.17M	Sell	14,165 -25,474	-64%	-$2.19M	0.03%	631
2016 Q3	$3.67M	Buy	39,639 +2,166	+6%	+$204K	0.09%	131
2016 Q2	$2.92M	Buy	37,473 +8,148	+28%	+$693K	0.06%	183
2016 Q1	$2.42M	Buy	29,325 +17,837	+155%	+$1.45M	0.07%	215
2015 Q4	$1.2M	Sell	11,488 -3,970	-26%	-$415K	0.02%	706
2015 Q3	$1.63M	Buy	15,458 +1,569	+11%	+$210K	0.03%	556
2015 Q2	$1.9M	Buy	13,889 +3,837	+38%	+$475K	0.03%	466
2015 Q1	$1.25M	Buy	10,052 +3,352	+50%	+$355K	0.03%	613
2014 Q4	$606K	Buy	+6,700	New	+$557K	0.01%	1464
2014 Q3	–	Sell	-3,675	Closed	-$229K	–	3594
2014 Q2	$229K	Sell	3,675 -9,673	-72%	-$584K	﹤0.01%	2892
2014 Q1	$910K	Buy	13,348 +4,779	+56%	+$352K	0.01%	1321
2013 Q4	$602K	Sell	8,569 -3,687	-30%	-$250K	0.01%	1744
2013 Q3	$885K	Buy	+12,256	New	+$815K	0.01%	1299

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu KCG Holdings's BMRN Position: Q2 2017 in Review

Virtu KCG Holdings increased its BioMarin Pharmaceuticals (BMRN) stake by 59% in Q2 2017, buying an estimated $832K and bringing the position to 24,643 shares worth $2.24M. The position accounts for 0.06% of the portfolio, ranked #211.

Virtu KCG Holdings first reported a position in BMRN in Q3 2013 and has held it in 15 quarters since. The position peaked at $3.67M in Q3 2016. 426 funds tracked by Wall St. Rank hold BMRN as of Q2 2017.

Virtu KCG Holdings held 24,643 shares of BioMarin Pharmaceuticals worth $2.24M as of Q2 2017.
Virtu KCG Holdings bought 9,149 BioMarin Pharmaceuticals shares in Q2 2017, an estimated $832K.
BioMarin Pharmaceuticals made up 0.06% of Virtu KCG Holdings's portfolio in Q2 2017, its #211 holding.
Virtu KCG Holdings first reported a position in BioMarin Pharmaceuticals in Q3 2013 and has held it in 15 quarters since.
Virtu KCG Holdings's BioMarin Pharmaceuticals position peaked at $3.67M in Q3 2016.
426 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.